Your search returned 3 results.

Results
	1.	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. [electronic resource] by Ramalingam, S S O'Byrne, K Boyer, M Mok, T Jänne, P A Zhang, H Liang, J Taylor, I Sbar, E I Paz-Ares, L Producer: 20161213 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 27 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. [electronic resource] by Ramalingam, S S O'Byrne, K Boyer, M Mok, T Jänne, P A Zhang, H Liang, J Taylor, I Sbar, E I Paz-Ares, L Publication details: Annals of oncology : official journal of the European Society for Medical Oncology 07 2016 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 27 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. [electronic resource] by Lacouture, M E Keefe, D M Sonis, S Jatoi, A Gernhardt, D Wang, T Doherty, J P Giri, N Nadanaciva, S O'Connell, J Sbar, E Piperdi, B Garon, E B Producer: 20180102 In: Annals of oncology : official journal of the European Society for Medical Oncology vol. 27 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)